Media ReleasesImugene Limited

View All Imugene Limited News

Imugene Announces PD-1 Cancer Vaccine Development Update

• New PD-1 cancer vaccine named KEY-Vaxx

• Phase 1 planning well advanced

• Preclinical results in validated models of colorectal (colon) cancer
demonstrate inhibitory cancer growth activity

MELBOURNE Australia 23 July 2018: Imugene Limited (ASX:IMU), a clinical stage immuno-oncology company is pleased to announce a development update of its newly acquired PD-1 cancer vaccine from Ohio State University. The check-point inhibitor cancer vaccine named KEY-Vaxx, demonstrates superior cancer growth inhibition compared with an industry-standard monoclonal antibody in validated models of colorectal (colon) cancer (CT26).

For further information please download PDF attached:
Download this document